News
ARWR
85.59
-1.90%
-1.66
Why Arrowhead Pharmaceuticals (ARWR) Is Back In The Spotlight
Simply Wall St · 1d ago
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Simply Wall St · 2d ago
Weekly Report: what happened at ARWR last week (0803-0807)?
Weekly Report · 3d ago
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/06 18:55
Arrowhead Pharmaceuticals Price Target Raised to $120.00/Share From $115.00 by HC Wainwright & Co.
Dow Jones · 08/06 18:55
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
Benzinga · 08/06 18:44
Arrowhead price target raised to $120 from $115 at H.C. Wainwright
TipRanks · 08/06 16:15
Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress
Simply Wall St · 08/06 01:42
Arrowhead: Buy Rating Reiterated as Redemplo Momentum Builds and Pipeline Catalysts Support Unchanged $120 Price Target
TipRanks · 08/05 13:56
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD)
TipRanks · 08/05 13:10
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)
TipRanks · 08/05 13:00
Arrowhead price target raised to $104 from $98 at Stifel
TipRanks · 08/05 11:14
Analysts’ Top Healthcare Picks: Vera Therapeutics (VERA), Arrowhead Pharmaceuticals (ARWR)
TipRanks · 08/05 09:00
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Vera Therapeutics (VERA)
TipRanks · 08/05 09:00
Arrowhead: Strong Phase III Plozasiran Data and Priority Review Voucher Drive Accelerated Path to Market and $3B Global Sales Outlook, Supporting Buy Rating
TipRanks · 08/05 06:56
Arrowhead Pharmaceuticals (ARWR) Gets a Buy from Chardan Capital
TipRanks · 08/05 02:56
Arrowhead reports Q3 EPS ($1.36), consensus ($1.23)
TipRanks · 08/04 20:12
Arrowhead acquires FDA priority review voucher
TipRanks · 08/04 20:07
Arrowhead Pharmaceuticals GAAP EPS of -$1.36 misses by $0.08, revenue of $75.23M beats by $31.22M
Seeking Alpha · 08/04 20:05
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Benzinga · 08/04 20:02
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.